C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on targeted protein degradation, reported a net loss of $105.0 million for the fiscal year ending December 31, 2025, a slight decrease from the $105.3 million loss recorded in 2024. The company has not yet generated revenue from product sales, relying instead on collaboration agreements, which yielded $35.9 million in revenue for 2025, a marginal increase from $35.6 million in the previous year. The revenue growth was primarily driven by increased contributions from collaborations with Merck KGaA and Roche, offset by a significant decline in revenue from Biogen as that collaboration concluded.
In terms of operational developments, C4 Therapeutics is advancing its clinical pipeline, which includes cemsidomide, an IKZF1 and IKZF3 degrader for multiple myeloma, and CFT8919, an EGFR L858R degrader for non-small-cell lung cancer. The company has initiated a Phase 2 trial for cemsidomide in combination with dexamethasone and is collaborating with Betta Pharma for the development of CFT8919 in Greater China. As of December 31, 2025, C4 Therapeutics employed 104 full-time staff, including 40 with advanced degrees, reflecting its commitment to building a skilled workforce to support its research and development efforts.
C4 Therapeutics has also made strategic moves to bolster its financial position, raising approximately $126.4 million in gross proceeds through an underwritten offering in October 2025. This funding is expected to support ongoing clinical trials and the development of its proprietary TORPEDO platform. The company had cash, cash equivalents, and marketable securities totaling approximately $297.1 million at year-end, which it believes will be sufficient to fund operations through 2028, although it acknowledges the need for additional capital to support its long-term objectives.
Looking ahead, C4 Therapeutics faces several challenges, including the need to secure regulatory approvals for its product candidates and the potential for increased competition in the biopharmaceutical space. The company is also navigating a complex landscape of healthcare regulations and reimbursement policies that could impact its commercialization efforts. Despite these challenges, C4 Therapeutics remains focused on advancing its clinical programs and expanding its pipeline, with the goal of addressing significant unmet medical needs in oncology and other therapeutic areas.
About C4 Therapeutics, Inc.
C4 Therapeutics is a clinical-stage biopharmaceutical company specializing in targeted protein degradation (TPD) to develop small-molecule medicines that eliminate disease-causing proteins. Leveraging its proprietary TORPEDO platform, the company designs oral, selective protein degraders primarily for oncology indications, including multiple myeloma, non-Hodgkin lymphoma, melanoma, colorectal, and non-small cell lung cancers. C4’s approach offers catalytic, durable, and highly selective therapies addressing unmet medical needs through innovative drug discovery and strategic collaborations.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.